Sugi Predict

Sugi Predict / Compounds / SCHEMBL4092804

SCHEMBL4092804

SCHEMBL4092804

O=C(O)CCCOc1ccc(CN(C(=O)Nc2ccc(C(=O)O)cc2)c2ccc(C3CCCCC3)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 12/20 0.64
▸ GIPR P48546 8/20 0.51
▸ STAT3 P40763 4/20 0.49
▸ GLP1R P43220 1/20 0.44
▸ FFAR4 Q5NUL3 1/20 0.41
▸ PTGES O14684 1/20 0.39
▸ ALOX5 P09917 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ GPR35 Q9HC97 1/20 0.39
▸ MITF O75030 1/20 0.39
▸ KLF5 Q13887 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2663112 0.92 GCGR (0.57) GCGRGIPRSTAT3GLP1RFFAR4
SCHEMBL2663125 0.89 GCGR (0.76) GCGRGIPRSTAT3GLP1R
SCHEMBL4092459 0.87 GCGR (0.55) GCGRGIPRSTAT3FFAR4MEN1
SCHEMBL4092003 0.83 GCGR (0.57) GCGRGIPRSTAT3GLP1RFFAR4
SCHEMBL2654645 0.79 GCGR (0.75) GCGRGIPRSTAT3GLP1R
SCHEMBL2646605 0.79 GCGR (0.77) GCGRGIPRSTAT3GLP1RMITF
SCHEMBL2654581 0.78 GCGR (1.00) GCGRGIPRGLP1R
SCHEMBL4095262 0.78 GCGR (1.00) GCGRGIPRGLP1R
SCHEMBL2653077 0.77 GCGR (0.77) GCGRGIPRGLP1R
SCHEMBL2659589 0.77 GCGR (0.77) GCGRGIPRGLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885STAT3 1079/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885STAT3 1079/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885STAT3 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.